Bladder Tumor Markers

Noridian Healthcare Solutions, LLC

Please Note: This is a Proposed LCD.
Proposed LCDs are works in progress and not necessarily a reflection of the current policies or practices. Proposed LCDs in an approval status display on the CMS MCD for public review.

Contractor Information

Noridian Healthcare Solutions, LLC

01112

A and B MAC

CMS National Coverage Policy

Title XVIII of the Social Security Act, §1862(a)(7) and 42 Code of Federal Regulations (CFR), §411.15, exclude routine physical examinations.

Title XVIII of the Social Security Act, §1833(e), prohibits Medicare payment for any claim lacking the necessary documentation to process the claim.

42 Code of Federal Regulations (CFR) §410.32 and §410.33, indicates that diagnostic
tests are payable only when ordered by the physician who is treating the beneficiary for a specific medical problem and who uses the results in such treatment.

CMS Internet-Only Manual, Publication 100-08, Medicare Program Integrity Manual, Chapter 3, §3.4.1.3, Diagnosis code requirements.

**Jurisdiction**  California - Northern

**Super MAC**  J - E

**Coverage Guidance**

**INDICATIONS**

Gross painless hematuria is often the first manifestation of a urothelial tumor. Since the degree of hematuria bears no relation to the seriousness of the underlying disease, the microscopic finding of blood in the urine is a serious symptom until significant pathology has been excluded.

At this time, there is no published consensus from the following national organizations: National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO), American Urological Association (AUA) and the International Bladder Cancer Consensus Group (IBCCG) regarding the management of persistent asymptomatic microscopic hematuria. Due to insufficient supporting data, the AUA’s 2001 best practices policy could not recommend routine use of voided urinary markers in the evaluation of patients with microscopic hematuria(3).

Recommended surveillance schedules for patients with a previous negative evaluation for unexplained microscopic hematuria include annual urinalysis and voided urinary cytology until the hematuria resolves, or for up to three years if microscopic hematuria persists. The AUA has been silent regarding practice guidelines due to the paucity of prevalence studies on asymptomatic microscopic hematuria.

Cystoscopy in conjunction with bladder tumor markers is the standard practice to evaluate patients with symptoms suggesting bladder cancer and to monitor treated patients for recurrence or progression. Although cystoscopy is considered
the “gold standard”, studies have shown that up to 20% of tumor can be missed. Urinary cytology has close to a 90%-100% specificity, but only 10%-50% sensitivity for low grade urinary cancer (UC) detection. Due to this deficit, clinicians have sought noninvasive tumor markers detectable in urine.

Upwards of 50% of patients have recurrence of bladder cancer within five (5) years.

After initial diagnosis and treatment, patients with UC are frequently monitored every three months for the first two years, every four months for the third year then usually twice a year for the fourth year. Annual monitoring is recommended during years 5 through 15.

Diagnostic and Surveillance Tests

- **BTA TRAK®** - a quantitative determination of human complement factor H-related protein
- **Nuclear matrix protein 22 (NMP-22)** – detects nuclear mitotic apparatus protein believed to be released during apoptosis; a quantitative assay, which is either positive of negative
- **NMP-22 BladderChek®** – a CLIA-waved assay, point of care test with immunochromographic qualitative format taking 20 minutes to perform
- **The UroVysion® Bladder Cancer Kit** is fluorescence in situ hybridization (FISH) DNA probe technology. It is designed to detect aneuploidy for chromosomes 3, 7, 17 and loss of the 9p21 locus. This assay involves visualization of nucleic acid sequences within cells by creating short sequences of fluorescently labeled, single-strand DNA probes that match target sequences. The probes bind to complementary strands of DNA to identify the targeted chromosome(s) location. It is used to detect chromosomal abnormalities in voided urine to assist not only in bladder cancer surveillance but also in the initial identification of bladder cancer.

Scientific studies demonstrate the sensitivity of BTA and NMP-22 are superior to urinary cytology (1, 6). Studies affirm the adjunctive value of BTA stat ® and NMP-22 in suspected and known bladder cancer in conjunction with cystoscopy. However, false positive results occur more frequently in the presence of hematuria, nephrolithiasis, recent GU instrumentation, inflammation and other urological malignancies. Administration of BCG within 2 years of testing decreases specificity to 28%.

The DNA probe assay has high sensitivity (81%) and specificity (96%) for high grade tumors but lower sensitivity (36-57%) for low grade and stage tumors. The assay specificity approaches that of cytology, and can be utilized in patients recently treated with intravesical bacillus Calmette-Guerin (BCG). This can result in a
positive Urovysion test with a negative study for UC. This assay has also been shown to be useful in predicting tumor recurrence following BCG therapy.

At present the IBCCG has recommended that tumor markers be used in conjunction with cystoscopy. They also concluded that routine screening for bladder cancer is not cost-effective (3). The US Preventive Services Task Force concluded bladder tumor markers do not have a proven role in screening of asymptomatic patients for early detection of bladder cancer. (3) NCCN, ASCO, and AUA are silent regarding the utilization of these bladder tumor markers.

**Surveillance Tests**

- **BTA (bladder tumor antigen)stat®** - a qualitative CLIA-waved test that identifies a human complement factor H-related protein produced by several human bladder cell lines

- **The ImmunoCyt ™** test is cleared for monitoring bladder cancer recurrence only in conjunction with cytology and cystoscopy. The assay uses fluorescent labeled antibodies to 3 markers (carcinoembryonic antigen, and mucins LDQ10 and M344) commonly found on malignant exfoliated urothelial cells. The ImmunoCyt assay has also been shown to be more sensitive than urine cytology.

**LIMITATIONS**

Bladder cancer tumor markers performed by immunoassay are ONLY considered medically necessary as an adjunct in the diagnosis and monitoring of bladder cancer *in conjunction* with cystoscopy.

Bladder cancer tumor markers performed by immunoassay are not covered for screening of all patients with hematuria. Bladder tumor markers are not expected until other diagnostic studies fail to identify the etiology of the hematuria.

All other bladder cancer marker assays, including but not limited to the following, regardless of the methodology are considered investigational and not covered by Medicare:

- BCLA-4
- BLCA-1
- Hyaluronic acid
- Hyaluronidase
- Lewis X antigen
• Microsatellite markers
• Quanticyt
• Soluble FAS TATI (tumor associated trypsin inhibitor)
• Soluble e-cadherin
• Survivin
• Telomerase
• UBC™ Rapid Test (urinary bladder cancer test for cytokeratins 8 and 18)

Proposed Process Information

Synopsis of Changes

Fields Changed

Not Applicable

Documentation Requirements

The medical record must clearly identify the number and frequency of bladder marker testing.

Medical record documentation must be legible, must be maintained in the patient’s medical record (hard copy or electronic copy), and must meet the criteria contained in this LCD and be made available to the A/B MAC upon request.

Utilization Guidelines

• Only one bladder cancer test per single date of service (e.g., FISH then reflex cytology) are considered reasonable and necessary.

• For high risk patients with persistent hematuria and a negative FISH assay following a comprehensive diagnostic (no tumor identified) workup, ONE repeat FISH testing in conjunction with cystoscopy is considered reasonable and necessary within 1 year of the original attempted diagnosis.
Follow-up after initial diagnosis and treatment

- Maximum of four (4) bladder tumor marker studies per year for years 1-2
- Maximum of three (3) bladder tumor marker studies per year for year 3
- Maximum of two (2) bladder tumor marker studies for year 4 and
- Maximum of one (1) bladder tumor marker studies follow-up annually for up to 15 years.

Sources of Information and Basis for Decision

1. BTA stat® test package insert.


<table>
<thead>
<tr>
<th>Open Meetings</th>
<th>Meeting Date</th>
<th>Meeting Information</th>
<th>State</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>06/02/2016</td>
<td>Los Angeles Airport Marriott Denver Room 5855 West Century Boulevard Los Angeles, CA 90045</td>
<td>American Samoa, California - Entire State, Guam, Hawaii, Nevada, Northern Mariana Islands, California - Northern, California - Southern</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Part B MAC Contractor Advisory Committee (CAC) Meetings</th>
<th>Meeting Date</th>
<th>Meeting Information</th>
<th>State</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>06/08/2016</td>
<td>Burlingame California - Entire State, California - Northern, California - Southern</td>
<td></td>
</tr>
<tr>
<td></td>
<td>06/03/2016</td>
<td>Honolulu Hawaii</td>
<td></td>
</tr>
<tr>
<td></td>
<td>06/09/2016</td>
<td>Las Vegas Nevada</td>
<td></td>
</tr>
</tbody>
</table>

| Comment Period Start Date | 06/02/2016 |
| Comment Period End Date  | 08/08/2016 |

| Released to Final LCD Date | Not yet released. |
| Reason for Proposed LCD | Creation of Uniform LCDs... |
|                          | Creation of Uniform LCDs With Other MAC Jurisdiction |

| Proposed LCD Contact | Noridian Healthcare Solutions, LLC JE Part B Contractor Medical Director(s) Attention: Draft LCD Comments PO Box 6783 Fargo, North Dakota 58108-6783 policyb.drafts@noridian.com |

<table>
<thead>
<tr>
<th>Coding Information</th>
<th>Proposed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bill Type Codes</td>
<td></td>
</tr>
</tbody>
</table>
Revenue Codes
99999 Not Applicable

Group 1: Paragraph
CPT CODES
To bill UroVysion Bladder Kit services bill 88120 or 88121 as appropriate.

Group 1: Codes
86294 IMMUNOASSAY FOR TUMOR ANTIGEN, QUALITATIVE OR SEMIQUANTITATIVE (EG, BLADDER TUMOR ANTIGEN)
86316 IMMUNOASSAY FOR TUMOR ANTIGEN, OTHER ANTIGEN, QUANTITATIVE (EG, CA 50, 72-4, 549), EACH
86386 NUCLEAR MATRIX PROTEIN 22 (NMP22), QUALITATIVE
88120 CYTOPATHOLOGY, IN SITU HYBRIDIZATION (EG, FISH), URINARY TRACT SPECIMEN WITH MORPHOMETRIC ANALYSIS, 3-5 MOLECULAR PROBES, EACH SPECIMEN; MANUAL
88121 CYTOPATHOLOGY, IN SITU HYBRIDIZATION (EG, FISH), URINARY TRACT SPECIMEN WITH MORPHOMETRIC ANALYSIS, 3-5 MOLECULAR PROBES, EACH SPECIMEN; USING COMPUTER-ASSISTED TECHNOLOGY

Does the CPT 30% Coding Rule Apply? No

Group 1: Paragraph

Group 1: Codes

ICD-10 Codes that Support Medical Necessity
C67.0 Malignant neoplasm of trigone of bladder
C67.1 Malignant neoplasm of dome of bladder
C67.2 Malignant neoplasm of lateral wall of bladder
C67.3 Malignant neoplasm of anterior wall of bladder
C67.4 Malignant neoplasm of posterior wall of bladder
C67.5 Malignant neoplasm of bladder neck
C67.6 Malignant neoplasm of ureteric orifice
C67.7 Malignant neoplasm of urachus

Note: Performance is optimized by using code ranges.
C67.8 Malignant neoplasm of overlapping sites of bladder
C67.9 Malignant neoplasm of bladder, unspecified
C7A.00 Malignant carcinoid tumor of unspecified site
C7A.098 Malignant carcinoid tumors of other sites
C7A.8 Other malignant neuroendocrine tumors
C7B.00 Secondary carcinoid tumors, unspecified site
C7B.09 Secondary carcinoid tumors of other sites
C7B.8 Other secondary neuroendocrine tumors
C7B.00 Secondary malignant neoplasm of unspecified lung
D09.0 Carcinoma in situ of bladder
D41.4 Neoplasm of uncertain behavior of bladder
D49.4 Neoplasm of unspecified behavior of bladder
R31.0 Gross hematuria
R31.1 Benign essential microscopic hematuria
R31.2* Other microscopic hematuria
R31.9 Hematuria, unspecified
Z78.9* Other specified health status
Z85.51* Personal history of malignant neoplasm of bladder

**Group 1: Asterisk**
R31.2 To be used only when repeat testing is believed to be medically reasonable and necessary, and must be listed as secondary with the primary neoplastic diagnosis.

Z78.9 To be used only when repeat testing is believed to be medically reasonable and necessary, and must be listed as secondary with the primary neoplastic diagnosis.

Z85.51 To be used only when repeat testing is believed to be medically
reasonable and necessary, and must be listed as secondary with the primary neoplastic diagnosis.

ICD-10 Codes that DO NOT Support Medical Necessity

Note: Performance is optimized by using code ranges.

Additional ICD-10 Information

Associated Documents

Attachments
There are no attachments for this LCD.

Related Local Coverage Documents
This LCD version has no Related Local Coverage Documents.

Related National Coverage Documents
This LCD version has no Related National Coverage Documents.

Version 6 - Updated on 04/27/2016 14:57:09, by Christine.Burnside@noridian.com, with effective dates N/A - N/A (Approved).
Version 5 - Updated on 04/26/2016 18:29:46, by Maggie.Abraham@noridian.com, with effective dates N/A - N/A.
Version 4 - Updated on 04/22/2016 11:10:28, by Maggie.Abraham@noridian.com, with effective dates N/A - N/A.
Version 3 - Updated on 04/18/2016 16:45:06, by Maggie.Abraham@noridian.com, with effective dates N/A - N/A.
Version 2 - Updated on 04/18/2016 16:07:57, by Maggie.Abraham@noridian.com, with effective dates N/A - N/A.
Version 1 - Updated on 04/18/2016 15:31:11, by Maggie.Abraham@noridian.com, with effective dates N/A - N/A.

Additional Information
Contractor Only Notes

- Bladder
- Tumor
- Markers
- UroVysion
- NMP-22
- BTA
- Trak
- ImmunoCyt
- 86294
- 86316
- 86386
- 88120
- 88121

Keywords

Saved By Christine.Burnside@noridian.com

Saved On 04/27/2016

Date Retirement Completed

Approved? Yes